US Stocks
Glaukos Corporation
Glaukos Corporation

Glaukos Corporation (GKOS)


  • $







Key Stats

Today Low/High$51.27 / $54.49
52 Week Low/High$39.35 / $99
P/E ratio-65.26
Market Cap$2.37B

Company Details

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
OrganisationGlaukos Corporation
HeadquatersSan Clemente, California, US
IndustryHealth Technology
CEOThomas Burns

Discover more

Frequently Asked Questions

What is Glaukos Corporation (GKOS) share price today?

Can Indians buy Glaukos Corporation (GKOS) shares?

How can I buy Glaukos Corporation (GKOS) shares from India?

Can Fractional shares of Glaukos Corporation (GKOS) be purchased?

What are the documents required to start investing in Glaukos Corporation (GKOS) stocks?